huN901-DM1: Interim Phase I data

Interim data from an open-label, dose-escalation, U.S. and U.K. Phase I study in 21 evaluable patients showed that huN901-DM1 was well tolerated. One of 4 patients at dose levels of 36 mg/m 2 daily or...